Mesenchymal Stem Cells Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 4.59 Billion |
| Market Size (2030) | USD 8.20 Billion |
| CAGR (2025 - 2030) | 12.29% |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Mesenchymal Stem Cells Market Analysis
The Mesenchymal Stem Cells Market size is estimated at USD 4.59 billion in 2025, and is expected to reach USD 8.20 billion by 2030, at a CAGR of 12.29% during the forecast period (2025-2030).
The mesenchymal stem cells (MSC) market is experiencing significant growth driven by several key factors. The expansion of research and development, alongside clinical trials for mesenchymal stem cell-based products, is an important contributor. Additionally, the rising applications of mesenchymal stem cells (MSCs) and increasing competition among key market players are propelling the market’s growth. The growing adoption of mesenchymal stem cell treatments for age-related ailments, the rising prevalence of chronic disorders, the rapid surge in cancer incidences, and the utilization of mesenchymal stem cells for stroke treatment and brain repair are expected to boost market growth during the forecast period.
Moreover, an exponential rise in MSC-based research and its implications in regenerative medicine fuel the market's growth. For instance, a report published by the Stem Cell Research and Therapy Journal in May 2024 mentioned that the phase II randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy of intrathecal mesenchymal stem cell-neural progenitors (MSC-NPs) in patients with progressive multiple sclerosis (MS). It showed promising improvements in walking speed, endurance, bladder function, and brain atrophy reduction, particularly in patients with higher disability levels.
While the primary outcome measure, Expanded Disability Status Scale Plus (EDSS Plus), did not show a significant difference between the MSC-NP and placebo groups, exploratory subgroup analyses indicated notable improvements in mobility and bladder function. These findings suggested promising therapeutic potential for patients with progressive multiple sclerosis. These results underscored the commercial potential and market growth of MSC-based therapies, particularly for conditions lacking effective treatments, thus attracting investment and development in the market.
The rising prevalence of chronic disorders and the rapid surge in cancer incidence are driving the growth of the market globally. For instance, according to a report published by the World Health Organization in February 2024, in 2022, over 20 million new cancer cases were reported, and 53.5 million individuals were living within five years of a cancer diagnosis. Approximately 20% of the global population is expected to develop cancer at some point in their lifetime.
The rise in cases of liver disease is also expected to propel the growth of the market. For instance, according to a report published by the government of the United Kingdom in April 2024, hospital admission rates for liver diseases increased to 155.2 per 100,000 people in the financial year ending 2023. The significant increase in cases, such as the 27,085 admissions for alcoholic liver disease, underscores the urgent need for advanced therapeutic options, thereby driving investment and development in mesenchymal stem cell-based treatments for liver regeneration and repair. Therefore, an increase in chronic diseases is estimated to boost market growth.
In addition, the constant development of stem cell therapies is projected to propel investments in the market with large-scale operational entities targeting small or emerging players with an acquisition strategy to expand their market presence. For instance, in August 2022, AGC Biologics partnered with RoosterBio Inc. to create an end-to-end solution for developing and producing human mesenchymal stem cells and exosome therapeutics. Therefore, the increasing advancements in stem cell therapies are driving market investments, characterized by major operational entities acquiring smaller players to enhance their market influence, exemplified by partnerships focused on developing and producing human mesenchymal stem cells and exosome therapeutics.
Therefore, owing to the abovementioned factors, the market is anticipated to grow over the forecast period. However, the need for standardized and regulated delivery of stem cell therapy, coupled with ethical concerns associated with human mesenchymal stem cell therapy, is expected to impede market growth.
Mesenchymal Stem Cells Market Trends
Cardiovascular Diseases Segment is Expected to Witness a Significant Growth Over the Forecast Period
Cardiovascular diseases (CVDs) are one of the leading chronic diseases worldwide. While existing treatment options such as bypass surgery and medications are available, their effectiveness is often limited, and they frequently come with side effects. This has driven the search for innovative therapeutic approaches, with mesenchymal stem cell therapy emerging as a particularly promising alternative.
The rising global burden of cardiovascular diseases significantly impacts market growth. Factors such as aging populations, unhealthy lifestyles, and increasing diabetes rates are contributing to the worldwide prevalence of CVDs, creating a substantial patient population in need of novel treatment options. For instance, according to the report published in the Government of Germany's Journal in September 2023, the German population's share of people aged 65 and above increased from 20.7% to 22.1% from 2012 to 2022, and it is estimated to reach 28% by 2050.
According to the British Heart Foundation's data, published in January 2024, around 7.6 million people in the United Kingdom lived with heart and circulatory diseases in 2023. Also, 2.3 million people, around 1.5 million men and 830,000 women, lived with congestive heart disease in the United Kingdom. Hence, the rise in cardiovascular diseases is expected to drive the market’s growth over the forecast period.
Encouraging clinical trial results is one of the primary segmental drivers. Early-stage and ongoing trials demonstrate the safety and efficacy of mesenchymal stem cell therapy for various CVDs, including myocardial infarction, heart failure, and peripheral artery disease. According to a report published in the Cureus Journal in August 2023, the increasing number of clinical trials exploring mesenchymal stem cell (MSC) therapy for heart failure is driving market growth by demonstrating significant improvements in left ventricular ejection fraction (LVEF) and reduced rehospitalization rates, thereby enhancing the therapeutic credibility and adoption of mesenchymal stem cells treatments. As more evidence supports the efficacy and safety of mesenchymal stem cell therapy, investment and interest in the market are likely to escalate, fostering advancements and commercial opportunities. Such positive outcomes are attracting significant investments, thereby fueling market expansion.
Therefore, the increasing prevalence of cardiovascular diseases, coupled with promising clinical trial outcomes and demographic trends like aging populations, is driving substantial growth in the market for treating various cardiovascular conditions.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
The North American market is expected to grow rapidly due to factors such as technological innovations, high R&D expenditure, and well-equipped healthcare centers. High disposable incomes, government initiatives, and the availability of advanced research facilities and skilled professionals are also among the key factors contributing to the market’s growth in North America.
Many clinical trials are underway to assess the efficacy and safety of mesenchymal stem cells as a viable treatment for several chronic diseases in the region. For instance, according to a report published in the Plos One Journal in July 2023, a favorable safety profile and promising clinical efficacy were observed in MSC therapies for rheumatoid arthritis (RA). Such trends drive increased interest and investment in the market. This growing confidence in mesenchymal stem cells’ therapeutic potential, supported by clinical evidence of safety and efficacy, positions mesenchymal stem cell-based treatments as compelling alternatives amid challenges associated with existing RA therapies, potentially expanding their adoption and market penetration.
Many major companies engaged in the supply and commercialization of mesenchymal stem cells are headquartered in the region, such as Thermo Fisher Scientific, Cell Applications Inc., and Cyagen Biosciences Inc. The concentration of crucial players in the region, along with enhanced supply chain efficiencies, product launches, and strategic collaborations, drives the growth of the market.
Key product launches, government initiatives, or manufacturers’ presence in the region are some of the factors driving the growth of the market. For instance, in July 2023, Merck announced the enhancement of its operations at the Lenexa, Kansas facility with an investment totaling EUR 23 million (USD 25 million), aimed at expanding laboratory space by 9,100 sq. m and bolstering production capacity for cell culture media. This strategic expansion is poised to catalyze growth in the market by ensuring robust supply chain capabilities and advanced research support.
Similarly, in January 2022, RoosterBio, a company that supplies human mesenchymal stem/stromal cells (hMSCs), media, and hMSC bioprocess systems, partnered with Univercells Technologies. The partnership aimed to optimize the manufacturing of extracellular vesicles (EVs) with the use of scalable and continuous bioprocessing technologies in order to advance the commercialization of regenerative therapies. Such continuous initiatives in the region are anticipated to drive the growth of the market.
Therefore, owing to the factors mentioned above, the mesenchymal stem cell market is anticipated to grow in North America.
Mesenchymal Stem Cells Industry Overview
The mesenchymal stem cells market is moderately fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies that hold market shares and are well known. Major market players include Thermo Fisher Scientific, Cell Applications Inc., Cyagen Biosciences Inc., Axol Bioscience Ltd, Stemcell Technologies Inc., Celprogen Inc., Merck KGaA (Millipore Sigma), Lonza Group Ltd, PromoCell GmbH, and ScienCell Research Laboratories.
Mesenchymal Stem Cells Market Leaders
-
Thermo Fisher Scientific
-
Cell Applications, Inc
-
Axol Bioscience Ltd.
-
STEMCELL Technologies Inc.
-
Cyagen Bioscience
- *Disclaimer: Major Players sorted in no particular order
Mesenchymal Stem Cells Market News
- April 2024: Memel Biotech, a contract development and manufacturing organization based in Lithuania, unveiled a comprehensive, advanced therapy development and manufacturing service at its Klaipeda facility to cater to markets within the European Union (EU). Through this initiative, Memel Biotech seeks to forge partnerships with emerging and established biotech firms aiming to venture into advanced therapy medicinal products (ATMPs). The company's manufacturing capabilities span a diverse range, including mesenchymal stem cells and chimeric antigen receptor T cells.
- February 2024: The University of Liverpool launched a new spin-out company, TrophiCell, that developed an approach to harness the therapeutic potential of adult mesenchymal stem cells (MSCs).
Mesenchymal Stem Cells Industry Segmentation
As per the scope of the report, mesenchymal stem cells (MSCs) are a type of multipotent stem cell that can differentiate into a variety of cell types, such as cartilage cells (chondrocytes), bone cells (osteoblasts), muscle cells (myocytes), and fat cells (adipocytes).
The mesenchymal stem cells market is segmented into products and services, type, source, indication, application, and geography. The products and services segment is further divided into products and services. The products segment is subdivided into kits, media and reagents, cells and cell lines, and other products. By type, the market is segmented into autologous and allogeneic. The source segment is further divided into adipose tissue, bone marrow, cord blood, fetal liver, and others. The indication segment is further divided into bone and cartilage repair, cardiovascular diseases, inflammatory and immunological diseases, liver diseases, cancer, graft vs host diseases, and others. The application segment is divided into disease modeling, drug development and discovery, stem cell banking, tissue engineering, toxicology studies, and others. The geography segment is further divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD) for all the above segments.
| By Products and Services | Products | Kits, Media, and Reagents | |
| Cells and Cell Lines | |||
| Other Products | |||
| Services | |||
| By Type | Autologous | ||
| Allogenic | |||
| By Source | Adipose Tissue | ||
| Bone Marrow | |||
| Cord Blood | |||
| Fetal Liver | |||
| Others | |||
| By Indication | Bone & Cartilage Repair | ||
| Cardiovascular Disease | |||
| Inflammatory and Immunological Disease | |||
| Liver Diseases | |||
| Cancer | |||
| Graft vs Host Disease | |||
| Others | |||
| By Application | Disease Modeling | ||
| Drug Development & Discovery | |||
| Stem Cell Banking | |||
| Tissue Engineering | |||
| Toxicology Studies | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Products | Kits, Media, and Reagents |
| Cells and Cell Lines | |
| Other Products | |
| Services |
| Autologous |
| Allogenic |
| Adipose Tissue |
| Bone Marrow |
| Cord Blood |
| Fetal Liver |
| Others |
| Bone & Cartilage Repair |
| Cardiovascular Disease |
| Inflammatory and Immunological Disease |
| Liver Diseases |
| Cancer |
| Graft vs Host Disease |
| Others |
| Disease Modeling |
| Drug Development & Discovery |
| Stem Cell Banking |
| Tissue Engineering |
| Toxicology Studies |
| Others |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Mesenchymal Stem Cells Market Research FAQs
How big is the Mesenchymal Stem Cells Market?
The Mesenchymal Stem Cells Market size is expected to reach USD 4.59 billion in 2025 and grow at a CAGR of 12.29% to reach USD 8.20 billion by 2030.
What is the current Mesenchymal Stem Cells Market size?
In 2025, the Mesenchymal Stem Cells Market size is expected to reach USD 4.59 billion.
Who are the key players in Mesenchymal Stem Cells Market?
Thermo Fisher Scientific, Cell Applications, Inc, Axol Bioscience Ltd., STEMCELL Technologies Inc. and Cyagen Bioscience are the major companies operating in the Mesenchymal Stem Cells Market.
Which is the fastest growing region in Mesenchymal Stem Cells Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Mesenchymal Stem Cells Market?
In 2025, the North America accounts for the largest market share in Mesenchymal Stem Cells Market.
What years does this Mesenchymal Stem Cells Market cover, and what was the market size in 2024?
In 2024, the Mesenchymal Stem Cells Market size was estimated at USD 4.03 billion. The report covers the Mesenchymal Stem Cells Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Mesenchymal Stem Cells Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Mesenchymal Stem Cells Industry Report
Statistics for the 2025 Mesenchymal Stem Cells market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Mesenchymal Stem Cells analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
